Goals for this Lecture. Case 1. Key Points MRI TECHNIQUES FOR DIFFERENTIAL DIAGNOSIS OF RECURRENT BRAIN LESIONS
|
|
- Beverley Lester
- 5 years ago
- Views:
Transcription
1 MRI TECHNIQUES FOR DIFFERENTIAL DIAGNOSIS OF RECURRENT BRAIN LESIONS Goals for this Lecture 1. Review common appearances for recurrent tumor and treatment effects on conventional MRI 2. Discuss current roles and limitations of anatomic MRI methods for assessing response versus recurrence 3. Outline the rationale for and practical application of physiologic MRI methods for problem solving Christopher P. Hess, M.D., Ph.D. Assistant Professor, Radiology & Biomedical Imaging Neuroradiology Chief, San Francisco VA Medical Center University of California, San Francisco Diffusionweighted MRI MR Perfusion Proton MR Spectrosopy Key Points Case 1 Never interpret imaging without treatment history and prior studies Anatomic MRI is very sensitive for assessing response to treatment, but has important shortcomings Before Physiologic MRI techniques can help... sometimes Antiangiogenic agents are game changers After
2 Case 2 Progression True Progression Pseudoprogression Before MRI Gad T1 Diffusion Perfusion Spectroscopy After Pseudoresponse Response True Response Treatment Response, 1990: Macdonald Criteria Macdonald et al, J Clin Oncol 1990; 8: Enhancement: Strengths Most high grade tumor enhances First objective criteria used for assessment of treatment response, enabled crosstrial comparison 4 categories: complete response, partial response, stable disease, progression 3 metrics, only 1 based on imaging Use of corticosteroids Changes in neurological status Enhancing tumor area = Weaknesses Measurement difficult when shape irregular Altered by MRI technique Modulated by medications Ignores multifocal tumor
3 Enhancement: Weaknesses (continued) Not all tumor enhances Cystic / necrotic tumor Infiltrative tumor Lowgrade tumor Enhancement: Reflects disruption of BBB from any cause Recurrence Radiation Necrosis Infarct Helpful Enhancement Patterns Treatment Mullins et al, AJNR 2005; 26: Kumar et al, Radiology 2000; 217: Recurrent Tumor Spread through corpus callosum Subependymal enhancement Enhancement in originally nonenhancing tumor Enhancement within port but remote from original tumor Periventricular location Soap bubble or Swiss chesse pattern Enhancement crossing through corpus callosum Subependymal enhancement Multiple solid enhancing lesions Multifocal enhancement
4 Postop Enhancement Soap bubbles Preop: GBM 24 hr postop: Gross total resection 2 months: Recurrence? Swiss cheese Periventricular Solution: Postop Diffusion MRI H + in CSF H + in WM H + in Infarct Diffusion MRI Reduced diffusion on 24 hr postop MRI Acute PCA Infarct DWI Courtesy Soonmee Cha, MD (UCSF Neuroradiology)
5 Timing for Postoperative MRI Ulmer et al, Neurology 2006; 67: year old with unresectable GBM 9/26 8/24 Postop MRI within first 48 hours Mass effect Postsurgical enhancement begins at 4872 hrs, imaging before this time best shows extent of resection Enhancment Diffusionweighted imaging for anticipated areas of postsurgical enhancement signal Tumor Progression? 11/31 9/26 8/24 Resection Median PFS ~ 7 mo Dx R.T. Progression
6 Resection Median PFS ~ 7 mo Classic Radiation Changes Dx Radiation R.T. Three categories of radiation encephalopathy: 1. Acute 2. Earlydelayed 3. Latedelayed Divided by time course, clinical presentation, pathology, and imaging findings Variable at each stage, depending on dose and focal versus wholebrain irradiation Earlydelayed can present diagnostic dilemma, ie pseudoprogression Pseudoprogression Chamberlain et al, J Neurooncol 2007; 82: 8182 Taal et al, Cancer 2008; 113: Brandes et al, J Clin Oncol 2008; 26: Patients treated with concurrent chemoradiation Similar to earlydelayed radiation changes but more exhuberant and earlier May also have deteriorating clinical status Up to 4749% of patients on concurrent temozolamide Methylation of MGMT promotor may predisposing to pseudoprogression
7 Pseudoprogression in a 65yearold patient with GBM Brandes et al, NeuroOncology 2008; 10: 3617 DSC Perfusion MRI A. Presurgical MRI scan. B. Postsurgical MRI scan. C. One month after combined TMZ & radio; adjuvant TMZ was continued. D. Four months later, during administration of maintenance TMZ E. Eight months later, during administration of maintenance TMZ RBC Gd Rapid T2*weighted imaging Injected gadolinium bolus modulates image intensity during bolus passage Dynamic changes in T2* intensity allow voxelwise calculation of local hemodynamic parameters Noninvasive microcirculation assessment (angiogenesis) T2* signal intensity 1000 [GdDTPA] 0.02 Tumor Perfusion Courtesy Soonmee Cha, MD (UCSF Neuroradiology)
8 Nontumor Perfusion Tumor or Radionecrosis? Tumor or Radionecrosis? Proton MR Spectroscopy Chemical shift (ppm) related to molecular composition Noninvasive assessment of metabolism CH3 Ratio 3:1 OH Chemical shift (ppm)
9 Important MRS Metabolites Normal 1 H MRS Short TE Spectroscopy Shift (ppm) Biologic Correlate Interpretation NAA 2.01 Neuronal integrity Tumor infiltration Cr 3.03 Energy available Cho 3.19 Membrane turnover Tumor proliferation Lac 1.31 Anaerobic metabolism Hypoxia Lipid Necrosis Cell death Gray matter White matter Normal 1 H MRS Long TE Spectroscopy NAA Neurons replaced / displaced High membrane turnover No necrosis or phagocytosis Cho Cr Cho Cr No Lac No Lipid T2 MRS (TE = 288 ms) NAA T2
10 Radiation Necrosis Recurrent Tumor Tumor metabolism Necrosis Lipid peaks only Perfusion & Spectroscopy Limitations 62 yearold with biopsy+ GBM 7/30 1/10 Distortion around bone, blood products, calcium, metal from surgery Mass effect Limited volume of coverage Enhancment Low signal to noise Sensitivity to motion (especially MRS) signal Sensitivity to ROI placement (especially MRP) Treatment Response?
11 Pseudoresponse Progression on Bevacizumab Norden et al, Neurology 2008; 70: Antiantigenic therapies VEGF bevacizumab (Avastin) VEGFr cediranib (Recentin) Reduce enhancement in as little as 12 days Reported radiologic response rate 2560% Little or no benefit in progressionfree survival Before After Progression on Bevacizumab Gerstner et al, J Clin Oncol 2010; 28: e91e92 DWI Treatment Response, 2010: RANO Criteria RANO Working Group, J Clin Oncol 2010: 28: Before After Same response categories as Macdonald criteria Also weighs steroid use and clinical status Considers timing of chemoradiation and isodose lines in assessment of progression versus response Omits measurement of cystic portions of tumor Considers both enhancement and signal Includes criteria for multifocal tumor
12 Treatment Response, 2010: RANO Criteria RANO Working Group, J Clin Oncol 2010: 28: Key Points Never interpret imaging without treatment history and prior studies Anatomic MRI is very sensitive for assessing response to treatment, but has important shortcomings Physiologic MRI techniques can help... sometimes Antiangiogenic agents are game changers Thank you for your attention! christopher.hess@radiology.ucsf.edu
Clinical Trials for Adult Brain Tumors - the Imaging Perspective
Clinical Trials for Adult Brain Tumors - the Imaging Perspective Whitney B. Pope, M.D., Ph.D. Department of Radiology David Geffen School of Medicine at UCLA August 22, 2015 1 Disclosure of Financial Relationships
More informationMRS and Perfusion of Brain Tumors
Department of Radiology University of California San Diego MRS and Perfusion of Brain Tumors John R. Hesselink, M.D. MRS & Perfusion of Brain Tumors Tumor histology Degree of malignancy Delineate tumor
More informationBrain Tumors: Radiologic Perspective
Brain Tumors: Radiologic Perspective Alberto Bizzi, M.D. Neuroradiology Humanitas Research Hospital Milan, Italy The job of the neuroradiologist in the work-up of brain tumors has quite changed in the
More informationFunctional aspects of anatomical imaging techniques
Functional aspects of anatomical imaging techniques Nilendu Purandare Associate Professor & Consultant Radiologist Tata Memorial Centre Functional/metabolic/molecular imaging (radioisotope scanning) PET
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationIncidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide
405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD
More informationGeneral Identification. Name: 江 X X Age: 29 y/o Gender: Male Height:172cm, Weight: 65kg Date of admission:95/09/27
General Identification Name: 江 X X Age: 29 y/o Gender: Male Height:172cm, Weight: 65kg Date of admission:95/09/27 Chief Complaint Sudden onset of seizure for several minutes Present illness This 29-year
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationLaura Tormoehlen, M.D. Neurology and EM-Toxicology Indiana University
Laura Tormoehlen, M.D. Neurology and EM-Toxicology Indiana University Disclosures! No conflicts of interest to disclose Neuroimaging 101! Plain films! Computed tomography " Angiography " Perfusion! Magnetic
More information1) Diffusion weighted imaging DWI is a term used to describe moving molecules due to random thermal motion. This motion is restricted by boundaries
1) Diffusion weighted imaging DWI is a term used to describe moving molecules due to random thermal motion. This motion is restricted by boundaries such as ligaments, membranes and macro molecules. Diffusion
More informationMagnetic Resonance Imaging for Prediction and Assessment of Treatment Response in Bevacizumab-Treated Recurrent Glioblastoma
Magnetic Resonance Imaging for Prediction and Assessment of Treatment Response in Bevacizumab-Treated Recurrent Glioblastoma The Harvard community has made this article openly available. Please share how
More informationAssessment of treatment response in high grade gliomas: RANO criteria usage for an accurate radiology report.
Assessment of treatment response in high grade gliomas: RANO criteria usage for an accurate radiology report. Poster No.: C-2167 Congress: ECR 2014 Type: Educational Exhibit Authors: F. Facal de Castro,
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 11 APRIL 10 2010 JOURNAL OF CLINICAL ONCOLOGY S P E C I A L A R T I C L E From the Center for Neuro-Oncology, Dana-Farber/Brigham and Women s Cancer Center; Division of Neurology, Brigham
More informationThe current treatment regimen for patients with
Neuro-Oncology 15(5):515 534, 2013. doi:10.1093/neuonc/nos307 Advance Access publication January 16, 2013 NEURO-ONCOLOGY Differentiating tumor recurrence from treatment necrosis: a review of neurooncologic
More informationDisclosures. Diffusion and Perfusion Imaging in the Head and Neck. Learning objectives ???
Disclosures No relevant financial disclosures Diffusion and Perfusion Imaging in the Head and Neck Ashok Srinivasan, MD Associate Professor Director of Neuroradiology University of Michigan Health System
More informationBevacizumab: A Controversial Agent Against High-Grade Gliomas
Tumor Bevacizumab: A Controversial Agent Against High-Grade Gliomas Sussan Salas, MD 1, Miguel Guzman, MD 2, Kevin Judy, MD 1 1 Department of Neurological Surgery, Thomas Jefferson University, Philadelphia,
More informationAntiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. /
Antiangiogenic drugs in unresectable glioblastoma Dra. Carmen Balañá. / Outcome for unresectable GBM Overall survival for unresectable GBM without further treatment is: 3 months at most. Radiotherapy increases
More informationDefining pseudoprogression in glioblastoma multiforme
European Journal of Neurology 2013, 20: 1335 1341 CME ARTICLE doi:10.1111/ene.12192 Defining pseudoprogression in glioblastoma multiforme E. Van Mieghem a, A. Wozniak b, Y. Geussens c, J. Menten c, S.
More informationRadiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem
Radiotherapy and Brain Metastases Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem 24-02-2017 Possible strategies Watchful waiting Surgery Postop RT to resection cavity or WBRT postop SRS
More informationCase Report. Case Report
AJNR Am J Neuroradiol 26:274 278, February 2005 Case Report Differential Chemosensitivity of Tumor Components in a Malignant Oligodendroglioma: Assessment with Diffusion-Weighted, Perfusion- Weighted,
More informationNeuroradiology/Head and Neck Imaging Review
Neuroradiology/Head and Neck Imaging Review Fatterpekar et al. Perfusion MRI in High-Grade Gliomas Neuroradiology/Head and Neck Imaging Review FOCUS ON: Girish M. Fatterpekar 1 Diogo Galheigo 1 Ashwatha
More informationProgression or Pseudoprogression? A Review of Post- Treatment MRI Appearances of Glioblastoma
Progression or Pseudoprogression? A Review of Post- Treatment MRI Appearances of Glioblastoma Poster No.: C-1770 Congress: ECR 2015 Type: Authors: Keywords: DOI: Educational Exhibit S. Abdulla, G. Kapoor,
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationCNS SESSION 3/8/ th Multidisciplinary Management of Cancers: A Case based Approach
CNS SESSION Chair: Ruben Fragoso, MD/PhD UC Davis Fellow: Michael Cardenas, MD UC Davis Panel: Gordon Li, MD Stanford Seema Nagpal, MD Stanford Jennie Taylor, MD UCSF HPI: 46 yo right handed woman who
More informationFacing pseudoprogression after radiotherapy in low grade gliomas
Editorial Facing pseudoprogression after radiotherapy in low grade gliomas Fernando Carceller 1,2, Henry Mandeville 3, Andrew D. Mackinnon 4, Frank Saran 3 1 Children and Young People s Unit, Paediatric
More informationClinical Management Protocol Chemotherapy [Glioblastoma Multiforme (CNS)] Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: GLIOBLASTOMA MULTIFORME (CNS) Patient information given at each stage following agreed
More informationCNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
More informationDisclosures 2/10/2017. RAIN 2017 Difficult Cases Session. Patient MC, Original Diagnosis, 9/2006. MRI 9/5/06, pre-op
Disclosures RAIN 2017 Difficult Cases Session Clinical trials research funding support from: Novartis Genentech/Roche Merck NEUROLOGY AND NEUROLOGICAL SURGERY Jennifer L. Clarke, MD, MPH Associate Professor
More informationStructural and functional imaging for the characterization of CNS lymphomas
Structural and functional imaging for the characterization of CNS lymphomas Cristina Besada Introduction A few decades ago, Primary Central Nervous System Lymphoma (PCNSL) was considered as an extremely
More informationNICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng99
Brain tumours (primary) and brain metastases in adults NICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng99 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationSCIENTIFIC PROGRAMME SNOLA UPDATE ON NEURO- ONCOLOGY th March
SCIENTIFIC PROGRAMME SNOLA UPDATE ON NEURO- ONCOLOGY 2016 24th March 13h 13h45 pathology case case parasellar meningeoma case : posterior fossa pediatric tumor 13h45 16h Imaging for CNS lymphomas Parasellar
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationDiffusion Tensor Imaging in brain tumours
Diffusion Tensor Imaging in brain tumours @MarionSmits, MD PhD Associate Professor of Neuroradiology Dept. of Radiology, Erasmus MC, Rotterdam (NL) Honorary Consultant and Reader UCLH National Hospital
More informationEnormous effort has been invested in clinical trials for malignant
Published February 13, 2008 as 10.3174/ajnr.A0963 REVIEW ARTICLE J.W. Henson S. Ulmer G.J. Harris Brain Tumor Imaging in Clinical Trials SUMMARY: There are substantial challenges in the radiologic evaluation
More informationInternational Journal of Research and Review E-ISSN: ; P-ISSN:
International Journal of Research and Review www.ijrrjournal.com E-ISSN: 2349-9788; P-ISSN: 2454-2237 Original Research Article Grading of Intracranial Neoplasms with MR Perfusion and MR Spectroscopy Niharika
More informationFUNCTIONAL MAGNETIC RESONANCE IMAGING IN FOLLOW-UP OF CEREBRAL GLIAL TUMORS
Anvita Bieza FUNCTIONAL MAGNETIC RESONANCE IMAGING IN FOLLOW-UP OF CEREBRAL GLIAL TUMORS Summary of Doctoral Thesis to obtain PhD degree in medicine Specialty Diagnostic Radiology Riga, 2013 Doctoral thesis
More informationParisa Mirzadehgan, MPH, CCRP
Parisa Mirzadehgan, MPH, CCRP Approved therapy for a newly diagnosed GBM patient includes surgical resection radiation & temozolomide Upon recurrence there are few approved options surgical implantation
More informationEmerging contrasts at ultrahigh fields" A. Dean Sherry
Emerging contrasts at ultrahigh fields" A. Dean Sherry Advanced Imaging Research Center Department of Radiology UT Southwestern Medical Center Department of Chemistry & Biochemistry, UT Dallas ADVANCED
More informationDespite maximum treatment, glioblastoma remains
CME ARTICLE Pseudoprogression of Brain Tumors Stefanie C. Thust, MD, 1,2,3 Martin J. van den Bent, MD, PhD, 4 and Marion Smits, MD, PhD 5 * This review describes the definition, incidence, clinical implications,
More informationPrimary Central Nervous System Lymphoma with Lateral Ventricle Involvement
The Open Medical Imaging Journal, 2012, 6, 103-107 103 Open Access Primary Central Nervous System Lymphoma with Lateral Ventricle Involvement Yumi Oie 1,*, Kazuhiro Murayama 1, Shinya Nagahisa 2, Masato
More informationNeuro-Oncology Advance Access published April 4, 2012
Neuro-Oncology Advance Access published April 4, 2012 Neuro-Oncology doi:10.1093/neuonc/nos070 NEURO-ONCOLOGY Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative
More informationNON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
More informationPublished January 15, 2015 as /ajnr.A4218
Published January 15, 2015 as 10.3174/ajnr.A4218 ORIGINAL RESEARCH BRAIN Diffusion and Perfusion MRI to Differentiate Treatment- Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationNewborn Hypoxic Ischemic Brain Injury. Hisham Dahmoush, MBBCh FRCR Lucile Packard Children s Hospital at Stanford
Newborn Hypoxic Ischemic Brain Injury Hisham Dahmoush, MBBCh FRCR Lucile Packard Children s Hospital at Stanford NO DISCLOSURES INTRODUCTION Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause
More informationSmall and Big Operations: New Tools of the Trade for Brain Tumors. Disclosure. Incidence of Childhood Cancer
Small and Big Operations: New Tools of the Trade for Brain Tumors Nalin Gupta MD PhD Chief, Division of Pediatric Neurosurgery Departments of Neurosurgery and Pediatrics University of California San Francisco
More informationBrain tumours (primary) and brain metastases in adults
Brain tumours (primary) and brain metastases in adults NICE guideline Draft for consultation, January 0 This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain
More informationDISTINCTION BETWEEN RECURRENT GLIOMA AND RADIATION INJURY USING MAGNETIC RESONANCE SPECTROSCOPY IN COMBINATION WITH DIFFUSION-WEIGHTED IMAGING
doi:10.1016/j.ijrobp.2006.12.001 Int. J. Radiation Oncology Biol. Phys., Vol. 68, No. 1, pp. 151 158, 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/07/$ see front
More informationB. Understanding radiation- and chemotherapy-induced changes after treatment of brain tumours
B. Understanding radiation- and chemotherapy-induced changes after treatment of brain tumours Poster No.: A-083 Congress: ECR 2015 Type: Invited Speaker Authors: Y. Özsunar; Aydin/TR Keywords: Neuroradiology
More informationJ Clin Oncol 26: by American Society of Clinical Oncology
VOLUME 26 NUMBER 13 MAY 1 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy
More informationMRI perfusion in determining pseudoprogression in patients with glioblastoma
Clinical Imaging 37 (2013) 41 49 MRI perfusion in determining pseudoprogression in patients with glioblastoma Robert J. Young a, b,, Ajay Gupta a, Akash D. Shah a, Jerome J. Graber c, Timothy A. Chan b,d,
More informationAmide Proton Transfer Imaging: A Novel MR Method for High-grade Brain Tumors.
Amide Proton Transfer Imaging: A Novel MR Method for High-grade Brain Tumors. Poster No.: C-1732 Congress: ECR 2013 Type: Scientific Exhibit Authors: M. Ida, M. Ishizuka, T. Suzuki, Y. Kubo, K. Hino, S.
More informationMarizomib (MRZ): Brain Penetrant Irreversible Pan-Proteasome Inhibitor
MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY Daniela Bota, MD, PhD 1, Annick Desjardins, MD,
More informationGlioblastoma: Current Treatment Approach 8/20/2018
Glioblastoma: Current Treatment Approach 8/20/2018 Overview What is Glioblastoma? How is it diagnosed How is it treated? Principles of Treatment Surgery, Radiation, Chemotherapy Current Standard of care
More informationImaging for suspected glioma
Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless
More informationOff-Label Treatments. Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease. Outline
Off-Label Treatments Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease Jennifer Clarke, MD, MPH Assistant Professor Division of Neuro-Oncology Depts of Neurological
More informationPlanning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement
Connelly et al. BMC Cancer (2016) 16:842 DOI 10.1186/s12885-016-2890-0 CASE REPORT Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement Jennifer
More informationCorrelation of Myo-inositol Levels and Grading of Cerebral Astrocytomas
AJNR Am J Neuroradiol 21:1645 1649, October 2000 Correlation of Myo-inositol Levels and Grading of Cerebral Astrocytomas Mauricio Castillo, J. Keith Smith, and Lester Kwock BACKGROUND AND PURPOSE: In a
More informationDOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES
DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES Marco Krengli Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale A. Avogadro THE STANDARD OF CARE
More informationImaging: When to get MRI, CT or PET-CT?
Imaging: When to get MRI, CT or PET-CT? Alina Uzelac, D.O. Assistant Clinical Professor Neuroradiology UCSF Department of Radiology and Biomedical Imaging San Francisco General Hospital Overview CT MRI
More informationBrain Schema March 2018
Breast Cancer w/brain Mets 14 2283 / Lilly Abemaciclib PO Breast Ca or Melanoma mets allowed Leptomeningeal mets excluded Want brain met tissue Melanoma w/brain Mets 14 2209 / Bristol Myers Squibb Nivolumab
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationResponse Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy
Curr Neurol Neurosci Rep (2013) 13:347 DOI 10.1007/s11910-013-0347-2 NEURO-ONCOLOGY (LE ABREY, SECTION EDITOR) Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in
More informationMALIGNANT GLIOMAS: TREATMENT AND CHALLENGES
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN
More informationRole of functional MRI in evaluating intraaxial brain tumors Advances and pitfalls.
Role of functional MRI in evaluating intraaxial brain tumors Advances and pitfalls. Poster No.: C-1685 Congress: ECR 2014 Type: Educational Exhibit Authors: A. R. Udare, A. Mahajan, S. Juvekar, P. Shetty,
More informationTreatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma: A case series.
School of Medicine Digital Commons@Becker Open Access Publications 2016 Treatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma:
More informationLIVER IMAGING TIPS IN VARIOUS MODALITIES. M.Vlychou, MD, PhD Assoc. Professor of Radiology University of Thessaly
LIVER IMAGING TIPS IN VARIOUS MODALITIES M.Vlychou, MD, PhD Assoc. Professor of Radiology University of Thessaly Hepatocellular carcinoma is a common malignancy for which prevention, screening, diagnosis,
More informationCNS, Neuroradiology brain, Radiation physics, MR, Complications, Neoplasia /ecr2014/C-0010
Cerebral radionecrosis: imaging features, differential diagnosis and developmental characteristics. Experience in our center, pictorial essay and literature rewiew. Poster No.: C-0010 Congress: ECR 2014
More informationLecture #16 Clinical 1 H Spectroscopy
Lecture #16 Clinical 1 H Spectroscopy Neurospectroscopy in clinical practice and research Body applications References P., Clinical MR Spectroscopy Techniques and Applications, Cambridge University Press,
More informationConcepts for a personalized neurosurgical oncology. XXIV Annual Conference Pietro Paoletti 27. November 2015
Concepts for a personalized neurosurgical oncology Jörg-Christian Tonn Dept. of Neurosurgery Ludwig-Maximilian University München Großhadern Germany XXIV Annual Conference Pietro Paoletti 27. November
More informationLara A. Brandão, MD a,b, *, Mark S. Shiroishi, MD c, Meng Law, MD c. mri.theclinics.com KEYWORDS KEY POINTS
Brain Tumors A Multimodality Approach with Diffusion- Weighted Imaging, Diffusion Tensor Imaging, Magnetic Resonance Spectroscopy, Dynamic Susceptibility Contrast and Dynamic Contrast-Enhanced Magnetic
More informationTarget Delineation in Gliomas. Prof PK Julka Department of Radiotherapy and Oncology AIIMS, New Delhi
Target Delineation in Gliomas Prof PK Julka Department of Radiotherapy and Oncology AIIMS, New Delhi 1 What is a glioma? A primary brain tumour that originated from a cell of the nervous system 2 Recommendations:
More informationPrognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status.
Prognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status. R. Zalazar, M.D. Hernández, M. Páramo, P. Slon, M. Millor Muruzabal, J. Solorzano
More informationPerfusion MRI. Youngkyoo Jung, PhD Associate Professor Radiology, Biomedical Engineering, and Clinical & Translational Science Institute
Perfusion MRI Youngkyoo Jung, PhD Associate Professor Radiology, Biomedical Engineering, and Clinical & Translational Science Institute Perfusion The delivery of blood to a capillary bed in tissue Perfusion
More informationRole of Perfusion CT Parameter Measurements in Differentiating Treatment Induced Necrosis from Recurrent Tumor
Journal of US-China Medical Science 12 (2015) 151-157 doi: 10.17265/1548-6648/2015.04.002 D DAVID PUBLISHING Role of Perfusion CT Parameter Measurements in Differentiating Treatment Induced Necrosis from
More informationGlioblastoma is a highly angiogenetic malignancy.
Glioblastoma is a highly angiogenetic malignancy silvia.hofer@usz.ch for glioma cells to expand further there are two possibilities.. .. lining up blood vessels (co-option, diffusion) cross section ....
More informationInnovative Multimodal Imaging Techniques in Brain Tumor Clinical Trials
Innovative Multimodal Imaging Techniques in Brain Tumor Clinical Trials Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology, Biomedical Physics, and Bioengineering Brain Tumor Imaging Laboratory
More informationCorrelation of quantitative proton MR spectroscopy with local histology from stereotactic brain biopsy to evaluate heterogeneity of brain tumors
Correlation of quantitative proton MR spectroscopy with local histology from stereotactic brain biopsy to evaluate heterogeneity of brain tumors Steve H. Fung, MD 1, Edward F. Jackson, PhD 2, Samuel J.
More informationMR spectroscopy in post-treatment follow up of brain tumors
The Egyptian Journal of Radiology and Nuclear Medicine (2011) 42, 413 424 Egyptian Society of Radiology and Nuclear Medicine The Egyptian Journal of Radiology and Nuclear Medicine www.elsevier.com/locate/ejrnm
More informationTo analyse whether ADC values have a correlation with survival or EGFR amplification status in glioblastoma
To analyse whether ADC values have a correlation with survival or EGFR amplification status in glioblastoma R. Zalazar, M. Páramo, M. Hernández, P. Domínguez, J.Etxano, P.García Barquín, H.Quiceno Arias,
More informationGlioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D)
Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D) *Neurosurgery Consultant, King Saud University, Riyadh, KSA *Adjunct Teaching Faculty, Neurosurgery, Stanford School Of Medicine,
More informationDisease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology
Neuro-Oncology Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology Alba A. Brandes, Alicia Tosoni, Federica Spagnolli, Giampiero Frezza, Marco
More informationGoing Past the Data for Temozolomide. J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D.
Going Past the Data for Temozolomide J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D. Departments of Medicine (JLV), Neurosurgery (JLV) and Pharmacy Practice (LRB)
More informationCitation Pediatrics international (2015), 57.
Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationThe Radiologic Evaluation of Glioblastoma (GBM) and Differentiation from Pseudoprogression
The Radiologic Evaluation of Glioblastoma (GBM) and Differentiation from Pseudoprogression Alexis Roy, Harvard Medical School, Year III Our Patient AB: Clinical Presentation 53 year old female with a past
More informationBenjamin M. Ellingson, Ph.D.
Simultaneous ph- and Oxygen-Weighted Metabolic Imaging of Brain Tumors using Multi-Echo Amine Chemical Exchange Saturation Transfer (CEST) Echo Planar Imaging Benjamin M. Ellingson, Ph.D. Associate Professor
More informationRelated Symposia in AAPM 2007
Related Symposia in AAPM 7 Functional and Physiological MR Imaging for Therapy Assessment Yue Cao,, Ph.D. Departments of Radiation Oncology and Radiology, University of Michigan President s s symposium:
More informationIMAGING OF INTRACRANIAL INFECTIONS
IMAGING OF INTRACRANIAL INFECTIONS Dr Carolina Kachramanoglou LYSHOLM DEPARTMENT OF NEURORADIOLOGY NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY Plan Introduce MR sequences that are useful in the diagnosis
More informationFDOPA, C11Choline, C11 Methionine. Dr K.G.Kallur
FDOPA, C11Choline, C11 Methionine Dr K.G.Kallur Why? 11C Methionine scan Had undergone resection Earlier. Post op recurrent hypercalcemia C11 Methionine Unable to see in Sestamibi scan Brain Tumor After
More informationNew Imaging Concepts in Central Nervous System Neoplasms
New Imaging Concepts in Central Nervous System Neoplasms Maarten Lequin Department of Pediatric Radiology Wilhelmina Children s Hospital/University Medical Center Utrecht New Imaging Concepts in Central
More informationMedia Release. Basel, 17 November 2012
Media Release Basel, 17 November 2012 Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy
More informationT2, T2*, ute. Yeo Ju Kim. Radiology, Inha University Hospital, Incheon, Korea
SY28-1 T2, T2*, ute Yeo Ju Kim Radiology, Inha University Hospital, Incheon, Korea T2 relaxation times relate to the rate of transverse magnetization decay, caused by the loss of phase coherence induced
More informationPediatr Blood Cancer 2014
Low grade Glioma! 40% of pediatric brain tumors Pathologically, anatomically, clinically and biologically heterogeneous Leptomeningeal metastases in 5% Frequently protracted clinical course Long-Term Outcome
More informationArmed Forces Institute of Pathology.
Armed Forces Institute of Pathology www.radpath.com Armed Forces Institute of Pathology Breast Disease www.radpath.org Armed Forces Institute of Pathology Interpretation of Breast MRI Leonard M. Glassman
More informationAssessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors
linicians may encounter unique challenges when evaluating the imaging response of GMs treated with immunotherapy and checkpoint inhibitors. Irena Orlov. Industrial feel 21. igital on canvas, 40" 60". ssessing
More informationMEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES
MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES Although response is not the primary endpoint of this trial, subjects with measurable disease will be assessed by standard criteria. For the purposes of this
More informationTHE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
More informationThe MRI Appearance of Tumefactive Demyelinating Lesions
ownloaded from www.ajronline.org by 37.44.198.148 on 12/05/17 from IP address 37.44.198.148. opyright RRS. For personal use only; all rights reserved The MRI ppearance of Tumefactive emyelinating Lesions
More informationMRI Applications in Radiation Oncology:
MRI Applications in Radiation Oncology: Physician s Perspective Jeff Olsen, MD Department of Radiation Oncology Washington University, St. Louis, MO Disclosures Washington University has research and service
More information